Relmada Therapeutics, Inc. (RLMD): Price and Financial Metrics
GET POWR RATINGS... FREE!
RLMD Stock Price Chart Interactive Chart >
RLMD Price/Volume Stats
| Current price | $22.21 | 52-week high | $39.66 |
| Prev. close | $20.63 | 52-week low | $16.23 |
| Day low | $20.81 | Volume | 355,800 |
| Day high | $22.41 | Avg. volume | 286,656 |
| 50-day MA | $24.30 | Dividend yield | N/A |
| 200-day MA | $22.73 | Market Cap | 666.10M |
Relmada Therapeutics, Inc. (RLMD) Company Bio
Relmada Therapeutics, Inc. is a clinical stage, public specialty pharmaceutical company who develops a variety of established drug products. The Company also researches and procures chemical entities with a focus on the treatment of pain.
Latest RLMD News From Around the Web
Below are the latest news stories about Relmada Therapeutics Inc that investors may wish to consider to help them evaluate RLMD as an investment opportunity.
Relmada posts topline data for lead asset in abuse potential trial against ketamineThe development stage biotech company, Relmada Therapeutics (NASDAQ:RLMD) announced on Wednesday the topline results from the human abuse potential (HAP) study for its lead candidate REL-1017, currently in Phase 3 development for major depressive disorder (MDD). The Phase 1 study was designed to assess the abuse potential of REL-1017 vs.... |
Relmada Aces REL-1017 Vs Ketamine Study For Abuse PotentialRelmada Therapeutics Inc (NASDAQ: RLMD) has announced topline results of the human abuse potential (HAP) study with REL-1017 for major depressive disorder or MDD. REL-1017 is a novel NMDA receptor (NMDAR) channel blocker and the Company's lead candidate. The results showed that all three doses of REL-1017 (25 mg, 75 mg, and 150 mg) tested in recreational drug users demonstrated a substantial (30+ points) and statistically significant difference vs. intravenous ketamine 0.5 mg/kg over 40 minutes |
Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Ketamine for Abuse PotentialRelmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced top-line results of the human abuse potential (HAP) study with REL-1017, a novel NMDA receptor (NMDAR) channel blocker and the company's lead candidate in Phase 3 development for the treatment major depressive disorder (MDD). |
Relmada Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare ConferenceRelmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 8:00am Eastern Time. |
Wall Street Analysts See a 231% Upside in Relmada Therapeutics, Inc. (RLMD): Can the Stock Really Move This High?The mean of analysts' price targets for Relmada Therapeutics, Inc. (RLMD) points to a 231.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
RLMD Price Returns
| 1-mo | N/A |
| 3-mo | 14.78% |
| 6-mo | 5.46% |
| 1-year | -36.45% |
| 3-year | 161.91% |
| 5-year | 455.25% |
| YTD | -1.42% |
| 2021 | -29.75% |
| 2020 | -17.77% |
| 2019 | 747.83% |
| 2018 | 53.33% |
| 2017 | -31.19% |
Loading social stream, please wait...